informed consent form regarding the purpose of therapy, possible results and authorizing publication. We administered tiapride at 75 mg/day for his irritability and aggression, but it was not effective. We then stopped the tiapride and started to administer risperidone at 2 mg/day. As his activities of daily life rapidly worsened, we stopped the risperidone immediately. After its cessation, he developed neuroleptic malignant syndrome (NMS), which included a decrease in the level of consciousness, increased fever, tachycardia, hyperreflexia, tremor, rigidity, over-sweating and polypnea. Blood chemical tests were as follows: Na 139, K 4.0, Cl 104, total protein 6.3, albumin 3.4, creatine phosphokinase 19 and WBC 9300. Intensive care, including cooling and i.v. drip infusion, was provided and he recovered after 2 days. This is the only report to suggest a relation between DNTC and NMS. Habuchi et al. reported on transactive response DNA binding protein of 43 kDa pathology in DNTC. They also pointed out that α-synucleinopathy was observed in eight of 10 cases.2 Therefore, we might speculate that DNTC is a strong risk factor of NMS, as in the case of dementia of Lewy bodies.
REFERENCES